RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $708
Author: Benzinga Newsdesk | October 29, 2025 11:56am
RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and raises the price target from $704 to $708.